Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

The label change also comes after GSK voluntarily withdrew another indication for Zejula as a late-line treatment for women with recurrent ovarian cancer, after it emerged that PARP inhibitors may ...

Zejula was first approved in 2017 as a monotherapy ... rates to platinum-based chemotherapy in the second-line advanced treatment setting, approximately 85% of patients will experience recurrence ...

Third quarter growth was driven by continued momentum from Experior add tab and Credelio Plus as well as the US and Brazil launch of ZEJULA late in September ... provide support on questions and ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...

Though it’s the most common skin condition in the United States, determining the best acne treatment for your skin is still challenging. Acne treatments include prescription medications ...